碘-125近距离放疗、外照射放疗联合短期或长期雄激素剥夺治疗高危局限性前列腺癌的三联疗法:多中心随机3期试验(TRIP/TRIGU0907)结果
这项3期随机试验在37家医院纳入332例高危局限性前列腺癌患者,比较6个月与30个月雄激素剥夺治疗(ADT)联合碘-125近距离放疗及外照射放疗的疗效。中位随访9.2年,7年生化进展累积发生率短程组9.0%、长程组8.0%(P=.65),次要终点无显著差异,三联疗法毒性可接受。
要点
- 7年生化进展累积发生率短程ADT组9.0%(95%CI 5.5-14.5)vs 长程ADT组8.0%(4.7-13.5),P=.65。
- 内分泌相关3级以上不良事件短程组0.6% vs 长程组1.8%(P=.62),放疗相关为1.2% vs 0.6%(P=.62)。
- superiority设计未能证明30个月ADT优于6个月ADT,作者认为需开展非劣效性研究进一步验证。
核心结论
- 在选定高危特征人群中,两治疗组疗效相似,三联疗法毒性可接受。
- 本优效性设计研究未能证明30个月ADT联合近距离放疗和外照射放疗比6个月ADT获得更好的生化控制。
- 作者认为需开展非劣效性研究以获得进一步证据支持这些初步结果。
研究设计与样本
- 多中心随机3期试验,在37家医院开展,纳入40至79岁、T2c-3a期、前列腺特异性抗原>20 ng/mL或Gleason评分>7的男性。
- 患者接受6个月ADT联合碘-125近距离放疗后外照射放疗,分层后随机分为短程组(不再进一步治疗)或长程组(额外24个月ADT)。
- 共332例患者随机分配至短程组165例和长程组167例,中位随访9.2年,采用竞争风险分析进行意向性治疗分析。
主要发现
- 7年生化进展累积发生率短程组9.0%(95%CI 5.5-14.5)vs 长程组8.0%(4.7-13.5),P=.65。
- 次要终点(临床进展、转移、挽救治疗、疾病特异性死亡率、总生存)两组间无显著差异。
- 内分泌相关3级以上不良事件短程组0.6% vs 长程组1.8%(P=.62),放疗相关3级以上不良事件短程组1.2% vs 长程组0.6%(P=.62)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本优效性设计研究未能证明30个月ADT优于6个月ADT,作者认为需开展非劣效性研究以获得进一步证据支持这些初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase 3 randomized investigation was designed to determine whether 30 months of androgen deprivation therapy (ADT) was superior to 6 months of ADT when combined with brachytherapy and external beam radiation therapy (EBRT) for localized high-risk prostate cancer. METHODS AND MATERIALS: This study was conducted at 37 hospitals on men aged 40 to 79 years, with stage T2c-3a, prostate-specific antigen >20 ng/mL, or Gleason score >7, who received 6 months of ADT combined with iodine-125 brachytherapy followed by EBRT. After stratification, patients were randomly assigned to either no further treatment (short arm) or 24 months of adjuvant ADT (long arm). According to the Phoenix definition of failure, the primary endpoint was the cumulative incidence of biochemical progression. Secondary endpoints included clinical progression, metastasis, salvage treatment, disease-specific mortality, overall survival, and grade 3+ adverse events. An intention-to-treat analysis was conducted using survival estimates determined using competing risk analyses. RESULTS: Of 332 patients, 165 and 167 were randomly assigned to the short and long arms, respectively. The median follow-up period was 9.2 years. The cumulative incidence of biochemical progression at 7 years was 9.0% (95% CI, 5.5-14.5) and 8.0% (4.7-13.5) in the short and long arms, respectively (P = .65). The outcomes of secondary endpoints did not differ significantly between the arms. Incidence rates of endocrine- and radiation-related grade 3+ adverse events for the short versus long arms were 0.6 versus 1.8% (P = .62) and 1.2 versus 0.6% (P = .62), respectively. CONCLUSIONS: Both treatment arms showed similar efficacy among selected populations with high-risk features. The toxicity of the trimodal therapy was acceptable. The present investigation, designed as a superiority trial, failed to demonstrate that 30-month ADT yielded better biochemical control than 6-month ADT when combined with brachytherapy and EBRT. Therefore, a noninferiority study is warranted to obtain further evidence supporting these preliminary results.
引用
- Yorozu A, Namiki M, Saito S, et al. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907). Int J Radiat Oncol Biol Phys. 2023. PMID: 37802225. doi:10.1016/j.ijrobp.2023.08.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。